In April last year, the initial results from the Phase 1 Stage 2 showed that 47 percent of the patients demonstrated positive safety and efficacy profile. Four of the patients had stable disease while one patient had complete response with incomplete hematologic recovery.
In a statement, Bio-Path President and CEO Peter Nielsen, said, “These updated interim data from Stage 1 of our Phase 2 study of prexigebersen in de novo AML patients give strong evidence of the safety and efficacy profile of our lead compound and underscore its potential to provide meaningful treatment improvement in this difficult-to-treat patient population,”
Additionally, Nielsen emphasized, “Prexigebersen with its efficacy and safety profile is an ideal combination candidate with frontline therapy. Our aim is to match prexigebersen with the leading frontline therapies to improve treatment options for patients.”
“Consequently, we maintain an in-depth knowledge of all new therapies and therapies in development. As the treatment landscape evolves, we continue to nimbly respond to those advances and the plans for our registration-directed clinical development program for prexigebersen as a treatment for AML reflects these changes,” he said.
